| Literature DB >> 35979364 |
Kevin Baßler1, Wataru Fujii1, Theodore S Kapellos1, Erika Dudkin2, Nico Reusch1, Ari Horne1, Benedikt Reiz3, Malte D Luecken4, Collins Osei-Sarpong5, Stefanie Warnat-Herresthal1, Lorenzo Bonaguro1,6,7, Jonas Schulte-Schrepping1, Allon Wagner8,9, Patrick Günther6, Carmen Pizarro10, Tina Schreiber10, Rainer Knoll1,6,11, Lisa Holsten1, Charlotte Kröger1,11, Elena De Domenico6,7, Matthias Becker6,7, Kristian Händler6,7, Christian T Wohnhaas12, Florian Baumgartner3, Meike Köhler3, Heidi Theis6,7, Michael Kraut6,7, Marc H Wadsworth13,14, Travis K Hughes15, Humberto J Ferreira6, Emily Hinkley6,7, Ines H Kaltheuner15, Matthias Geyer16, Christoph Thiele17, Alex K Shalek13,14, Andreas Feißt17, Daniel Thomas17, Henning Dickten3, Marc Beyer5,6,7, Patrick Baum18, Nir Yosef8,9,19,20, Anna C Aschenbrenner11,20,21, Thomas Ulas1,6,7, Jan Hasenauer2,4, Fabian J Theis4,22, Dirk Skowasch10, Joachim L Schultze1,6,7.
Abstract
Despite its high prevalence, the cellular and molecular mechanisms of chronic obstructive pulmonary disease (COPD) are far from being understood. Here, we determine disease-related changes in cellular and molecular compositions within the alveolar space and peripheral blood of a cohort of COPD patients and controls. Myeloid cells were the largest cellular compartment in the alveolar space with invading monocytes and proliferating macrophages elevated in COPD. Modeling cell-to-cell communication, signaling pathway usage, and transcription factor binding predicts TGF-β1 to be a major upstream regulator of transcriptional changes in alveolar macrophages of COPD patients. Functionally, macrophages in COPD showed reduced antigen presentation capacity, accumulation of cholesteryl ester, reduced cellular chemotaxis, and mitochondrial dysfunction, reminiscent of impaired immune activation.Entities:
Keywords: TGF-β1; blood; bronchoalveolar lavage; chronic obstructive pulmonary disease; impaired immune activation; macrophage; monocyte
Mesh:
Year: 2022 PMID: 35979364 PMCID: PMC9377018 DOI: 10.3389/fimmu.2022.917232
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786